During the past decade, Wake Forest University Eye Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wake Forest University Eye Center" #1 sponsor was "Jaeb Center for Health Research" with 7 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Wake Forest University" with 2 trials sponsored, "Wake Forest University Health Sciences" with 2 trials sponsored and "Allergan" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wake Forest University Eye Center" #1 collaborator was "National Eye Institute (NEI)" with 7 trials as a collaborator, "Allergan" with 3 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Wake Forest University Eye Center" are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (3 trials), "Geographic Atrophy" (3 trials), "Macular Degeneration" (3 trials) and "Proliferative Diabetic Retinopathy" (2 trials). Many other conditions were trialed in "Wake Forest University Eye Center" in a lesser frequency.

Most popular intervention types in "Wake Forest University Eye Center" are "Drug" (18 trials), "Procedure" (4 trials), "Other" (3 trials), "Behavioral" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ranibizumab" (3 trials), "Sham Procedure" (3 trials), "Lampalizumab" (2 trials), "Placebo" (2 trials) and "0.3 mg intravitreal ranibizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Wake Forest University Eye Center" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Wake Forest University Eye Center". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Wake Forest University Eye Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Wake Forest University Eye Center, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".